A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma

Yang Zhang1, Fan Luo2, Yu-Xiang Ma1, Qian-Wen Liu1, Yun-Peng Yang2, Wen-Feng Fang2, Yan Huang2, Ting Zhou2, Jin Li3, Hong-Ming Pan4, Lei Yang5, Shu-Kui Qin6,*,‡, Hong-Yun Zhao1,*, Li Zhang2,*

1Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China
2Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China
3Department of Medical Oncology, Tongji University Shanghai East Hospital, Shanghai, People’s Republic of China
4Department of Internal Medical Oncology, Zhejiang University School of Medicine, Sir Run Run Shaw Hospital, Hangzhou, People’s Republic of China
5Haihe Biopharma Co., Ltd, Shanghai, People’s Republic of China
6PLA Cancer Center of Bayi Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China

*Corresponding authors: Li Zhang, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, People’s Republic of China; Email: zhangli6@mail.sysu.edu.cn; or, Hong-Yun Zhao, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, People’s Republic of China; Email: zhaohy@sysucc.org.cn; or, Shu-Kui Qin, PLA Cancer Center of Bayi Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China; Email: qinsk@csco.org.cn

‡Principal Investigator: Shu-Kui Qin

Abstract

Background: Lucitanib is a novel multi-target inhibitor of FGFR1-3, VEGFR 1-3, and PDGFR α/β. Here, we evaluated the safety, tolerability, and preliminary efficacy of lucitanib in recurrent and metastatic nasopharyngeal carcinoma (RM-NPC).

Methods: Patients with pretreated RM-NPC were randomly divided into two treatment arms: continuous or intermittent treatment. The primary endpoint was safety and tolerability. Secondary endpoints were objective response rate (ORRI), disease control rate (DCR), and progression-free survival (PFS).

Results: One hundred percent of patients in the continuous arm and 90% of patients in the intermittent arm had at least one treatment-related AE (TRAE). Grade ≥3 related TRAEs occurred in 5 patients in the continuous arm (5/10, 50%). No TRAEs grade >3 occurred in the intermittent arm. The ORR and DCR of the continuous arm was 20% and 90%, and the intermittent arm was 10% and 60%, respectively. All responses were observed by the first evaluation. The duration of response was more than 1 year, with two patients still on treatment with sustained response at more than 3 years.

Conclusion: Lucitanib has promising clinical activity and tolerable safety profile in heavily pretreated patients with NPC. Patients who responded to lucitanib treatment generally achieved a long DoR. Lucitanib is now being evaluated in phase II/III studies.

ClinicalTrials.gov identifier: NCT03260179

Key words: anti-angiogenic therapy; kinase inhibitor; AL3810; phase I trial; nasopharyngeal carcinoma

Lessons Learned

• Molecularly targeted therapy is a promising treatment strategy for patients with nasopharyngeal carcinoma (NPC) following tumor progression after failure of platinum-based chemotherapy.

• Preliminary data from this phase-Ib study showed that lucitanib, as a novel multi-target inhibitor of FGFR1-3, VEGFR 1-3, and PDGFR α/β, was well tolerated with favorable pharmacokinetics and showed encouraging anti-tumor activity in heavily pretreated patients with NPC.

Received: 26 August 2021; Accepted: 30 November 2021.
© The Author(s) 2022. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
The data published online to support this summary are the property of the authors. Please contact the authors about reuse rights of the original data.
Nasopharyngeal carcinoma (NPC) is prevalent in Southeast Asia, with an incidence of 20-50 cases per 100,000 people. Currently, platinum-based therapy is the first-line palliative care treatment for advanced NPC patients. However, there is still no standard salvageable therapeutic strategy for patients who experience failure from the original platinum-based regimen. Therefore, effective therapies for patients with advanced NPC are urgently needed. Lucitanib (AL3810), an oral tyrosine kinase inhibitor that targets fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and the platelet-derived growth factor receptor α/β (PDGFR α/β), has been evaluated in a phase I/IIa study for the clinical activity and adverse effects of lucitanib in patients with advanced solid tumors. The results showed that, in patients with angiogenesis-sensitive disease, the ORR was 26% and the median PFS was 25 weeks, while patients with FGF-aberrant breast cancer achieved a 50% partial response with a median PFS of 40.4 weeks. Other clinical trials for metastatic breast cancer and lung cancer have also demonstrated that lucitanib has promising efficacy and manageable side-effects in anti-tumor therapy. However, there are no clinical data to evaluate the anti-tumor activity of lucitanib in patients with advanced NPC. Here, we explore the safety profile and therapeutic efficacy of lucitanib in patients with RM-NPC.

Patients were randomly divided into two treatment groups: a continuous arm (n = 10) or intermittent arm (n = 10). All patients who received lucitanib therapy experienced at least one TEAE. Grade ≥3 related TEAEs occurred in 7 patients (7/20, 35%), including 5 patients in the continuous arm (5/10, 50%) and 2 in the intermittent arm (2/10, 20%). No patients experienced serious TRAEs. The most frequent grade ≥3 TRAEs were hypertension (30% vs 0%), proteinuria (20% vs 0%), increased AST (10% vs 0%), and decreased platelet count (10% vs 0%), in the continuous and intermittent arms, respectively—which were all on-target toxicities. With appropriate supportive treatment, dose reduction and/or temporary interruption, all TRAEs were manageable.

The therapeutic efficacy of lucitanib in patients with NPC was summarized in Figure 1. The ORR was 20% in the continuous arm and 10% in the intermittent arm. The DCR reached 90% in the continuous arm and 60% in the intermittent arm. The median PFS for patients in the continuous arm was 3.73 months (90% CI, 3.5 to NE months) and 3.68 months (90% CI, 1.74 to 7.36 months) in the intermittent arm. The PK profiles in patients with NPC were similar to a previous clinical lucitanib study.

In conclusion, lucitanib once daily continuous treatment showed a manageable side-effect profile and promising efficacy in RM-NPC patients. Further safety and efficacy assessments of lucitanib are being evaluated in phase II/III studies.

**Trial Information**

| Disease                          | Nasopharyngeal carcinoma |
|---------------------------------|---------------------------|
| Stage of disease/treatment      | Metastatic/advanced       |
| Prior therapy                   | No designated number of regimens |
| Type of study                   | Phase I, phase IIb, multi-centre, open-label |
| Primary endpoints               | Safety, tolerability      |
| Secondary endpoints             | Objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) |
| Investigator’s analysis         | Active and should be pursued further |

**Additional Details of Endpoints or Study Design**

**Patient Selection and Treatment**

Eligible patients had histologically or cytologically confirmed NPC that had recurred at locoregional and/or distant sites that were unamenable to curative treatment. The target lesions were measured according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. All patients must have received at least one prior line of platinum-based chemotherapy for recurrent disease and had adequate organ

---

**Figure 1.** Waterfall plot. The percentage of tumor dimension from baseline. The response evaluation criteria was as follows: Partial response (PR) referred to at least 30% decline in tumor dimension and progressive disease >20% increase.
function. Patients underwent baseline contrast-enhanced computed tomography of the chest, abdomen, and pelvis, and magnetic resonance imaging or computed tomography scanning for locoregional disease. Radiologic assessments were performed every 8 weeks. Archived tumor samples were retrieved. Eligible patients were randomly divided into two treatment arms: continuous daily dosing on a 4-week cycle, or intermittent treatment (3 weeks on/1 week off). The treatments were terminated when patients experienced disease progression, intolerable toxicity, or death.

Assessments
Each of the two arms was evaluated separately. The primary endpoint was the safety profile. Toxicity was graded according to the Common Terminology Criteria for Adverse Event version 4.03. The secondary endpoint was preliminary efficacy involving objective response rate (ORR), defined as the proportion of patients with a complete response (CR) or a partial response (PR) as the best overall response, evaluated by the investigator according to the RECIST version 1.1. Other secondary endpoints included DCR and PFS. Disease control rate was defined as the proportion of patients with a confirmed CR or a confirmed PR or prolonged stable disease (SD; according to the RECIST criteria for at least 4 weeks from randomization) during treatment. Exploratory endpoints were to characterize the biological activity of lucitanib on soluble growth factors of interest, tumor cells and to explore potentially predictive responses to lucitanib in blood samples and in primary archived specimens or metastatic tumors.

This is an exploratory study. Therefore, no formal sample size calculation was carried out. This study is planned to enroll patients in five cohorts, including gastric cancer (GC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), nasopharyngeal carcinoma (NPC) and thymic tumor. Each cohort is 1:1 randomized into continuous medication group or intermittent medication group. Each group of each cohort will include 10 patients, total 100 patients. The study was early terminated according to strategy adjustment. Finally, 44 patients were enrolled, including 20 NPC, 10 BTC, 6 GC, 4 HCC, and 4 thymic tumor. Here, we reported the data in a cohort of patients with recurrent and metastatic NPC.

Pharmacokinetic Analysis
In the two arms, pharmacokinetic (PK) assessment was conducted on cycle 1, day 1 (C1D1) after a single-dose administration and on cycle 1, day 15 (C1D15) after multiple-dose administrations. Blood samples were collected on day 1 and day 15 at 0 hours (predose), and then at 0.5, 1, 2, 3, 4, 8, and 12 hours post-dose, and pre-dose on C1D2, C1D16, C2D1, and C2D15. Blood samples were centrifuged and plasma frozen at a refrigeration of −80 ± 5°C until further analysis. AL3810 plasma concentrations were measured using a confirmed liquid chromatography-tandem mass spectrometry method.

Pharmacokinetic parameters after single-dose administration included: time to reach maximum plasma concentration (T_{max}), maximum plasma concentration (C_{max}), area under the plasma concentration-time curve from 0 to 24 hours after administration (AUC_{0-24h}). The area under the drug concentration-time curve from 0 to the last measurable concentration (AUC_{ss}), the area under the drug concentration-time curve from 0 to infinity (AUC_{0-∞}), terminal phase elimination rate constant (λ_{t}), the elimination half-life (t_{1/2}), apparent total clearance (CL/F), the apparent volume of distribution (V/F), extrapolated percentage of AUC_{0-∞} (% AUC_{0-∞}), and mean residence time (MRT).

Pharmacokinetic parameters after multiple-dose administrations included: steady-state peak concentration (C_{ss, max}), steady-state trough concentration (C_{ss, min}), steady-state mean plasma concentration (C_{ss, avg}), steady-state peak time (T_{ss, max}), area under the plasma concentration-time curve for steady state (AUC_{ss}), λ_{t}, t_{ss}, steady-state apparent clearance (CL_s/F), steady-state apparent volume of distribution (V_s/F), fluctuation coefficient (% Fluctuation), accumulation ratio based on AUC (R_{ss, AUC}), and C_{max} (R_{ss, C_{max}}). Descriptive statistics were measured for the PK parameters using the mean with its corresponding standard deviation (SD).

Statistics and Sample Size Calculation
Patients who signed the informed consent (including failed screening and successful screening) were pooled in the inclusion set (IS). Patients in the IS who took at least one dose of lucitanib were pooled in the safety set (SS). The qualitative and quantitative results are presented as descriptive statistics. The baseline patient characteristics and safety were carried out on the SS. The efficacy was assessed in the full analysis set. The Kaplan-Meier method was used to estimate PFS. The 90% CIs were calculated for PFS to evaluate the efficacy of the two cohorts. Fisher’s exact test compared the response rate in the different subgroups. Two-sided tests were applied. A P-value of < .05 was identified as statistically significant. All analyses were carried out using the Statistical Package for Social Science (SPSS) 23.0.

### Drug Information

| Generic/working name | Lucitanib |
|----------------------|-----------|
| Company name         | Haihe Biopharma Co., Ltd, Shanghai, China |
| Drug type            | Small molecule |
| Drug class           | Angiogenesis |
| Dose                 | 10 mg |
| Route                | oral (p.o.) |
| Schedule of administration | Intermittent arm: 3 weeks on/1 week off Continuous arm: continuous daily dosing on a 4-week cycle |
**Patient Characteristics: Intermittent Arm**

| Characteristic                        | Value          |
|--------------------------------------|----------------|
| Number of patients, male             | 8              |
| Number of patients, female           | 2              |
| Stage                                | i.v (10)       |
| Age                                  | Median (range): 43.5 (20, 65) |
| Number of prior systemic therapies   |                |
| Performance Status: ECOG             | • 0—5          |
|                                     | • 1—5          |
|                                     | • 2—0          |
|                                     | • 3—0          |
|                                     | • Unknown—0    |
| Other                                | See Table 1 for detailed patient characteristics |
| Cancer types or histologic subtypes  | Undifferentiated NPC 10 |

**Patient Characteristics: Continuous Arm**

| Characteristic                        | Value          |
|--------------------------------------|----------------|
| Number of patients, male             | 7              |
| Number of patients, female           | 3              |
| Stage                                | IV (9); unknown (1) |
| Age                                  | Median (range): 45.5 (25, 52) |
| Number of prior systemic therapies   |                |
| Performance status: ECOG             | • 0—7          |
|                                     | • 1—3          |
|                                     | • 2—0          |
|                                     | • 3—0          |
|                                     | • Unknown—0    |
| Other                                | See Table 1 for detailed patient characteristics |
| Cancer types or histologic subtypes  | Undifferentiated NPC 10 |

**Primary Assessment Method: Intermittent Arm**

| Title                                      | Efficacy   |
|--------------------------------------------|------------|
| Number of patients screened                | 10         |
| Number of patients enrolled                | 10         |
| Number of patients evaluable for toxicity  | 10         |
| Number of patients evaluated for efficacy  | 10         |
| Evaluation method                          | RECIST 1.1 |
| Response assessment CR                      | n = 0 (0%) |
| Response assessment PR                      | n = 1 (10%)|
| Response assessment SD                      | n = 5 (50%)|
| Response assessment PD                      | n = 3 (30%)|
| Response assessment OTHER                   | n = 1 (10%)|
| (Median) duration assessments PFS          | 3.68 months|

**Outcome Notes**

See Figure 1, Figure 2, and Table 4 for detailed response data. Tables 2 and 3 summarize adverse events. Figs. 1 and 2, and Table 4 report detailed response data.
For patients with advanced NPC, combination therapy with cisplatin and 5-fluorouracil is the most frequently used first-line regimen, with a high response rate of 66-78% and a median PFS of 11-14 months. Recently, the first phase III trial for RM-NPC, the landmark GEM20110714 study, established gemcitabine plus cisplatin (GP) as the standard first-line treatment. However, for patients with RM-NPC, there is no suitable second-line treatment regimen to choose from after failure of the platinum-based first-line treatment. Therefore, an effective second-line therapy is urgently needed for this group of patients.

Molecularly targeted therapy mainly involves drugs that bind to oncogenes to inhibit tumor progression and angiogenesis. They have been widely explored in RM-NPC. One of them is axitinib. Axitinib is a potent VEGFR inhibitor reported to achieve a 19% ORR and 78.4 DCR in 37 recruited patients with RM-NPC, with a median PFS and an overall survival (OS) of 5 and 10 months, respectively. Another is apatinib, which was evaluated in 51 relapsed and refractory patients with NPC who had no response to first- or second-line chemotherapy. The results demonstrated an ORR of 31.4% (16/51), with a median PFS of 9 months and OS of 16 months. A phase II study also investigated the treatment efficacy of pazopanib in 33 patients with NPC. The ORR was 6.1% and the DCR was 54.5% at 3 months. Fatimatinib was also reported in a phase II trial to achieve an ORR of 6.9%, a DCR of 32.8% at 3 months and a median PFS of 3.2 months in 58 NPC patients as reported in an abstract. Although these therapeutic agents showed a modest response rate in NPC patients, all these reports were single arm, had a small sample size, were exploratory trials, and most of them were investigator initiated. In a systematic review, aggregating estimates of OS and PFS for RM-NPC in first- and second-line or higher treatment settings, for patients in the second-line and beyond, current therapies only had moderate antitumor activity with ORRs ranging from 0% to 48% with a median PFS of 5.2-5.4 months and a median OS of 11.5-12.5 months.

Our study is the first to investigate the safety and therapeutic efficacy of lucitanib in patients with RM-NPC. Our results show that lucitanib has potential efficacy in NPC. In patients receiving continuous lucitanib treatment, we observed an objective response in 20% of patients and disease control in 90% of patients, and the median PFS was 3.73 months (90% CI, 3.5 to NE months). In all three of the responders, a PR was obtained at the first evaluation and lasted more than 1 year. Two of them were still on treatment (as of the cutoff date of the last follow-up), with a sustained response of more than 3 years. Overall, lucitanib demonstrated potently promising therapeutic activity and high disease control. Thus, lucitanib might be a potential treatment option for NPCs.

Identifying effective tumor response biomarkers helps doctors to screen patients for potential clinical benefits, which aligns with the personalized tumor treatment paradigm. Previous studies have shown that FGFR1 or FGF amplification may be a biomarker for lucitanib therapy in advanced cancers. A phase I/IIa study reported that the ORR in patients with FGF-aberrant (FGFR1- or FGFR3/4/19-amplified) breast cancer reached 50% and the median PFS was 40.4 weeks, which was superior to those with angiogenesis-sensitive solid tumors (ORR of 26% and PFS of 25 weeks). Angiogenesis-sensitive refers to a histological tumor type that responds to antiangiogen-based therapy or develops new progression after at least 6 months of stability. AL3810 is a multi-angiogenic tyrosine kinases inhibitor that significantly targets VEGF, FGFR, and PDGFR kinases. Its targets are similar to erdafitinib (FGFR1-4, VEGFR-2, and PDGFR-α/β). A study of molecular assays has shown that AL3810 and sorafenib showed similar potency against VEGFR2 and PDGFR, but AL3810 was more potent against FGFR than sorafenib. Another clinical trial in HR+/HER2-metastatic breast cancer demonstrated that lucitanib achieved a higher ORR in patients with high FGFR1 amplification than those without high amplification (22% vs. 9%). Given that VEGFR was overexpressed in 60% of clinical NPC samples and associated with a poor prognosis, further explorations of the biomarker are warranted to identify patients who may benefit from lucitanib treatment.

A recent study found that an early decrease in plasma EBV DNA copy number correlated with a favorable response of RM-NPC patients treated with immunotherapy, which is consistent with previous reports showing that the dynamic changes in EBV titer are closely related to chemotherapy and radiotherapy response. Although we collected baseline plasma EBV-DNA information when patients enrolled in our study, unfortunately we did not monitor this change, especially when patients responded or progression occurred. Dynamic EBV-DNA changes need further exploration as a predictor of lucitanib treatment efficacy in RM-NPC patients.

According to previous studies, a continuous 15 mg daily dose was unsustainable beyond three cycles due to arterial hypertension related to the antiangiogenic effect of lucitanib,

| Title | efficacy |
|-------|----------|
| Evaluation method | RECIST 1.1 |
| Response assessment CR | n = 0 (0%) |
| Response assessment PR | n = 2 (20%) |
| Response assessment SD | n = 7 (70%) |
| Response assessment PD | n = 1 (10%) |
| Response assessment OTHER | n = 0 (0%) |
| (Median) duration assessments PFS | 3.73 months |
as such the dose was reduced to 10 mg. Following these results, we selected 10 mg as the treatment dose in this study and randomly divided the patients into two cohorts: continuous daily treatment or intermittent treatment (3 weeks on/1 week off). The most frequent treatment-related AE (TRAES) grade ≥3 were hypertension (30% vs 0%), proteinuria (20% vs 0%), increased AST (10% vs 0%), and decreased platelet count (10% vs 0%), which is similar to other clinical lucitanib studies. This suggests that intermittent treatment could significantly improve the safety profile of lucitanib in patients with NPC. With suitable supportive treatment, dose reduction and/or temporary discontinuation, all TRAEs grade ≥3 can be effectively managed. Hypothyroidism was also one of the most common TRAEs in NPC patients (60% vs 50%), which is consistent with the toxicity profile of other multi-target tyrosine kinase inhibitors such as sunitinib, but it can be easily managed with thyroid hormone supplementation.

Lucitanib was rapidly absorbed with a median Tmax of 1.00 and 2.02 hours in the continuous and intermittent arms, respectively. The observed trough levels suggest that the steady state is reached by day 15. At the steady state, lucitanib exposure (Cmax, AUCO-24h) was approximately two to three times of that on day 1. Detailed pharmacokinetic parameters are listed in Tables 5 and 6. The PK parameters of lucitanib in NPC patients were consistent with those in a previous clinical lucitanib study, which supports lucitanib once daily administration.

In conclusion, continuous once daily lucitanib treatment showed promising clinical activity in RM-NPC patients. Patients who responded lucitanib generally achieved a long duration of response. Although the TRAE grade ≥3 for continuous treatment was numerically higher than intermittent treatment, all the AEs were on target side effects, which were predictable and manageable. While our sample size was comparatively small and the overall survival data was immature for analysis our results merit further evaluation in follow-up studies.

Click here to access other published clinical trials.

Acknowledgments

Y.Z. and F.L. contributed equally to this work. We would like to thank all patients, their families, study investigators and personnel for participating in this trial.

Funding

This research was sponsored by Haihe Biopharma Co., Ltd. This research was funded by the following grants, Guangdong Basic and Applied Basic Research Foundation (2020A1515011464); Natural Science Foundation of Guangdong Province (2018A0303130243); National Natural Science Foundation of China (81872201, 82073396, 82020268); Postdoctoral Science Foundation of China (2019M660227).

Conflict of Interest

The authors indicated no financial relationships.

Data Availability

The data underlying this article will be shared on reasonable request to the corresponding author.

References

1. Razak AR, Siu LL, Liu FF, Ito E, O’Sullivan B, Chan K. Nasopharyngeal carcinoma: the next challenges. Eur J Cancer. 2010;46(11):1967-1978.
2. Pfister DG, Spencer S, Adelstein D, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(7):873-898.
3. Soria JC, DeBraud F, Bahlada R, et al. Phase II/III study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol. 2014;25(11):2244-2251.
4. Hui R, Pearson A, Cortes J, et al. Lucitanib for the treatment of hr(+)her2(-) metastatic breast cancer: results from the multicohort phase II finesse study. Clin Cancer Res. 2020;26:334-363.
5. Pilotto S, Novello S, Peretti U, et al. An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer. Expert Opin Investig Drugs. 2015;24(9):1143-1161.
6. Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388(10054):1883-1892.
7. Hui EP, Ma BBY, Loong HHH, et al. Efficacy, safety, and pharmacokinetics of Axitinib in nasopharyngeal carcinoma: a preclinical and phase II correlative study. Clin Cancer Res. 2018;24(5):1030-1037.
8. Li L, Kong F, Zhang L, et al. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. Invest New Drugs. 2020;38(6):1847-1853.
9. Lim WT, Ng QS, Ivy P, et al. A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin Cancer Res. 2011;17(16):5481-5489.
10. Huang Y, Zhang L, Pan J-J, et al. A phase ii, multicenter, open-label, single-arm trial of farnitinib in patients with advanced recurrent and/or metastatic nasopharyngeal carcinoma (npc) after two previous treatment regimens. J Clin Oncol. 2013;31:6026-6026.
11. Prawira A, Oosting SF, Chen TW, et al. Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review. Br J Cancer. 2017;117(12):1743-1752.
12. D’Angelo A, Bagby S, Galli IC, Bortoletti C, Roviello G. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand. Expert Rev Clin Pharmacol. 2020;13(10):1139-1146.
13. Zhou Y, Chen Y, Tong L, et al. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR. J Cell Mol Med. 2012;16(10):2321-2330.
14. Hui EP, Chan AT, Pezzella F, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res. 2002;8(8):2595-2604.
15. Wang FH, Wei XL, Feng J, et al. Efficacy, safety, and correlative biomarkers of Toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a Phase II Clinical Trial (PO-LARIS-02). J Clin Oncol. 2021;39(7):704-712.
16. Chan ATC, Hui EP, Nguyen KRC, et al. Analysis of plasma epstein-barr virus dna in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol. 2018. Epub ahead of print.
17. Wang WY, Twu CW, Chen HH, et al. Plasma eBV dna clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res. 2010;16:1016-1024.
18. Abu-khalaf MM, Mayer IA, Tankersley C, et al. A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer. J Clin Oncol. 2015;33(suppl 15):Abstract TPS628.
19. André F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. *Clin Cancer Res.* 2013;19(13):3693-3702.

20. Campone M, Bachelot T, Penault-Llorca F, et al. A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer. *Cancer Chemother Pharmacol.* 2019;83(4):743-753.

21. Daimon M, Kato T, Kaino W, et al. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. *Jpn J Clin Oncol.* 2012;42(8):742-747.

**FIGURES AND TABLES**

**Figure 2.** Swimmer plot. Duration of response and time to response in patients receiving Lucitanib. CR, complete response; PD, progressive disease; PR, partial response.
### Table 1. Baseline characteristics of enrolled NPC patients.

| Characteristics                        | Continuous arm ($n = 10$) | Intermittent arm ($n = 10$) |
|----------------------------------------|---------------------------|----------------------------|
| Age, years, median, (max, min)         | 45.5 (25, 52)             | 43.5 (20, 65)              |
| Sex (male/female)                      | 7/3                       | 8/2                        |
| ECOG status (0/1)                      | 7/3                       | 5/5                        |
| Histology (WHO)                        | Undifferentiated NPC      | Undifferentiated NPC       |
| Distant metastasis (no/yes)            | 1/9                       | 0/10                       |
| Time since diagnosis, years, median    | 4.0 (1.0, 9.0)            | 3.0 (2.0, 9.0)             |
| TNM stage at primary diagnosis         |                           |                            |
| IIIA                                   | 1 (10%)                   | 1 (10%)                    |
| IIIB                                   | 0                         | 0                          |
| IV                                     | 4 (40%)                   | 6 (60%)                    |
| Unknown                                | 3 (30%)                   | 3 (30%)                    |
| TNM stage when study started           |                           |                            |
| IIA                                    | 0                         | 0                          |
| IV                                     | 9 (90%)                   | 10 (100%)                  |
| Unknown                                | 1 (10%)                   | 0                          |
| Previous lines of therapy              |                           |                            |
| 1                                      | 4 (20%)                   | 4 (20%)                    |
| 2                                      | 3 (30%)                   | 2 (20%)                    |
| ≥3                                     | 3 (30%)                   | 4 (40%)                    |
| EBV-DNA status                         |                           |                            |
| Positive                               | 7                         | 5                          |
| Negative                               | 1                         | 3                          |
| Missing                                | 2                         | 2                          |

NPC, nasopharyngeal carcinoma; TNM, tumor node metastasis classification; PR, partial response; CR, complete response; SD, stable disease; PD, progressive disease.

### Table 2. Drug-related adverse events with an incidence >10% in all patients.

| Preferred term          | Continuous arm ($n = 10$) $n$ (%) | Intermittent arm ($n = 10$) $n$ (%) |
|-------------------------|-----------------------------------|-------------------------------------|
| All                     | 10 (100.0)                        | 9 (90.0)                            |
| Hypertension            | 10 (100.0)                        | 4 (40.0)                            |
| Proteinuria             | 10 (100.0)                        | 5 (50.0)                            |
| Hypothyroidism          | 6 (60.0)                          | 5 (50.0)                            |
| AST increased           | 4 (40.0)                          | 0                                   |
| TSH increased           | 3 (30.0)                          | 1 (10.0)                            |
| Backache                | 4 (40.0)                          | 0                                   |
| Diarrhea                | 3 (30.0)                          | 0                                   |
| Skin rash               | 3 (30.0)                          | 0                                   |
| Epistaxis               | 5 (50.0)                          | 4 (40.0)                            |
| Hypochloremia           | 3 (30.0)                          | 1 (10.0)                            |
| Weight loss             | 4 (40.0)                          | 0                                   |
| Serum creatinine (Scr) increased | 4 (40.0) | 1 (10.0) |
| Platelet count decreased | 3 (30.0)                          | 1 (10.0)                            |
| Free thyroxine decreased | 3 (30.0)                          | 1 (10.0)                            |
| Cough                   | 2 (20.0)                          | 3 (30.0)                            |

### Table 3. The summary of TEAEs and TRAEs in continuous arm and intermittent arm.

| Adverse events (%)       | Continuous arm ($n = 10$) $n$ (%) | Intermittent arm ($n = 10$) $n$ (%) |
|--------------------------|-----------------------------------|-------------------------------------|
| Any grade TEAE           | 10 (100)                          | 10 (100)                            |
| Grade ≥3 TEAE            | 5 (50)                            | 2 (20)                              |
| Grade ≥3 TRAE            | 5 (50)                            | 0                                   |
| Serious TRAE             | 0                                 | 0                                   |
| TRAE lead to dose reduction | 4 (40)                          | 0                                   |
| TRAE lead to dose interruption | 5 (50)                        | 2 (20)                              |
| TRAE lead to dose discontinuation | 0                               | 1 (10)                              |

TEAE, treatment-emergent adverse events; TRAE, treatment-related adverse events.

### Table 4. Summary of antitumor activities of lucitanib.

| Best response (%)        | Continuous arm ($n = 10$) $n$ (%) | Intermittent arm ($n = 10$) $n$ (%) |
|--------------------------|-----------------------------------|-------------------------------------|
| PR                       | 2 (20)                            | 1 (10)                              |
| SD                       | 7 (70)                            | 5 (50)                              |
| PD                       | 1 (10)                            | 3 (30)                              |
| ORR                      | 20%                               | 10%                                 |
| DCR                      | 90%                               | 60%                                 |
| PK parameters | Statistics | Continuous arm (n = 5) | Intermittent arm (n = 4) |
|---------------|------------|------------------------|-------------------------|
| $C_{\text{max}}$ (ng/mL) | Mean ± SD | 293.20 ± 139.58 | 254.00 ± 147.86 |
| | GeoMean(%CVb) | 260.62(64.42) | 227.86(55.29) |
| $T_{\text{max}}$ (hour) | Median | 1.00 | 2.02 |
| | Min, max | 0.50, 2.00 | 0.50, 2.95 |
| $\text{AUC}_{0-24\text{h}}$ (ng*hour/mL) | Mean ± SD | 2558.30 ± 857.95 | 3109.42 ± 1887.72 |
| | GeoMean(%CVb) | 2405.22(44.55) | 2772.60(56.26) |
| $\text{AUC}_{0-t}$ (ng*hour/mL) | Mean ± SD | 2513.64 ± 833.77 | 3026.47 ± 1754.46 |
| | GeoMean(%CVb) | 2366.10(44.09) | 2723.82(53.79) |
| CL/F (L/hour) | Mean ± SD | 75.22 ± 40.20 | 60.82 ± 19.84 |
| | GeoMean(%CVb) | 68.00(51.77) | 58.08(37.66) |
| $\lambda_v$ (1/hour) | Mean ± SD | 0.03 ± 0.01 | 0.03 ± 0.01 |
| | GeoMean(%CVb) | 0.03(45.08) | 0.03(55.97) |
| $t_{1/2}$ (hour) | Mean ± SD | 23.79 ± 11.81 | 24.78 ± 15.46 |
| | GeoMean(%CVb) | 21.93(45.08) | 22.05(55.97) |
| $%\text{AUC}_{ex}$ (%) | Mean ± SD | 48.16 ± 10.87 | 47.96 ± 15.75 |
| | GeoMean(%CVb) | 47.22(22.24) | 46.33(29.69) |
| MRT (hour) | Mean ± SD | 34.20 ± 14.29 | 36.28 ± 21.57 |
| | GeoMean(%CVb) | 32.21(38.53) | 32.65(52.83) |
Table 6. The PK parameters of AL3810 from multiple-dose administration.

| PK parameters          | Statistics     | Continuous Arm (n=5)       | Intermittent Arm (n=4)       |
|------------------------|----------------|----------------------------|-----------------------------|
| $C_{ss,\text{max}}$ (ng/mL) | Mean ± SD     | 482.80 ± 271.81            | 608.50 ± 169.48             |
|                        | GeoMean(%CVg) | 435.78(50.87)              | 590.42(29.26)               |
| $C_{ss,\text{min}}$ (ng/mL) | Mean ± SD     | 203.46 ± 93.47             | 303.00 ± 117.86             |
|                        | GeoMean(%CVg) | 176.24(77.90)              | 284.37(44.50)               |
| $C_{ss,\text{avg}}$ (ng/mL) | Mean ± SD     | 277.72 ± 109.76            | 403.39 ± 154.68             |
|                        | GeoMean(%CVg) | 257.16(49.01)              | 381.64(40.16)               |
| $T_{ss,\text{max}}$ (hour) | Median        | 2.97                       | 1.98                        |
|                        | Min, Max      | 0.95, 4.00                 | 0.93, 4.00                  |
| $\text{AUC}_{ss}$ (ng*hour/mL) | Mean ± SD     | 6665.30 ± 2634.20          | 9681.40 ± 3712.42           |
|                        | GeoMean(%CVg) | 6171.82(49.01)             | 9159.28(40.16)              |
| $\lambda_z$ (1/hour)  | Mean ± SD     | 0.02 ± 0.01                | 0.02 ± 0.01                 |
|                        | GeoMean(%CVg) | 0.01(99.37)                | 0.02(55.07)                 |
| $CL/F$ (L/hour)       | Mean ± SD     | 1.78 ± 0.93                | 1.15 ± 0.45                 |
|                        | GeoMean(%CVg) | 1.62(49.01)                | 1.09(40.16)                 |
| $V/F$ (L)             | Mean ± SD     | 163.32 ± 140.17            | 55.84 ± 17.90               |
|                        | GeoMean(%CVg) | 125.47(94.88)              | 53.61(34.32)                |
| %Fluctuation (%)      | Mean ± SD     | 104.26 ± 61.47             | 81.15 ± 21.54               |
|                        | GeoMean(%CVg) | 90.75(63.71)               | 79.03(27.10)                |
| $R_{\text{nc},\text{AUC}}$ | Mean ± SD     | 2.62 ± 0.55                | 3.38 ± 0.84                 |
|                        | GeoMean(%CVg) | 2.57(22.45)                | 3.30(25.14)                 |
| $R_{\text{nc},\text{Cmax}}$ | Mean ± SD     | 1.98 ± 1.20                | 2.67 ± 0.69                 |
|                        | GeoMean(%CVg) | 1.67(77.55)                | 2.59(29.36)                 |
| $R_{\text{Cmin,D15}}$ | Mean ± SD     | 0.99 ± 0.3410              | 1.00 ± 0.28                 |
|                        | GeoMean(%CVg) | 0.94(34.42)                | 0.97(27.66)                 |